Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of SSGJ-611 in healthy volunteers
NCT04527718Phase 1Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SSGJ-611 in atopic dermatitis (AD) (5 cohorts), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events up to 90 days. Started Sep 2020; status: completed.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04527718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527718.